WAVE Life Sciences (WVE) Insider Sells $1,426,995.00 in Stock

WAVE Life Sciences (NASDAQ:WVE) insider Paul Bolno sold 31,711 shares of the firm’s stock in a transaction that occurred on Wednesday, May 30th. The stock was sold at an average price of $45.00, for a total transaction of $1,426,995.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paul Bolno also recently made the following trade(s):

Get WAVE Life Sciences alerts:

On Wednesday, May 2nd, Paul Bolno sold 18,289 shares of WAVE Life Sciences stock. The stock was sold at an average price of $45.00, for a total transaction of $823,005.00.

WVE stock traded up $1.95 during midday trading on Wednesday, reaching $46.85. The company had a trading volume of 299,414 shares, compared to its average volume of 157,962. WAVE Life Sciences has a 1 year low of $15.15 and a 1 year high of $55.95. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -12.17 and a beta of 0.65.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Wednesday, May 9th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.36). WAVE Life Sciences had a negative return on equity of 76.93% and a negative net margin of 2,613.03%. The company had revenue of $1.42 million during the quarter, compared to analysts’ expectations of $6.59 million. research analysts anticipate that WAVE Life Sciences will post -4.78 EPS for the current year.

A number of equities analysts recently commented on the stock. BidaskClub raised shares of WAVE Life Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday. ValuEngine raised shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. Mizuho raised their price objective on shares of WAVE Life Sciences from $34.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, March 19th. Leerink Swann decreased their price objective on shares of WAVE Life Sciences from $64.00 to $62.00 and set an “outperform” rating for the company in a research note on Tuesday, March 13th. Finally, SunTrust Banks raised their price objective on shares of WAVE Life Sciences to $60.00 and gave the stock a “buy” rating in a research note on Friday, March 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. WAVE Life Sciences presently has an average rating of “Buy” and a consensus price target of $53.40.

A number of hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in shares of WAVE Life Sciences during the 1st quarter valued at $330,000. Redmile Group LLC raised its holdings in shares of WAVE Life Sciences by 1.3% during the 1st quarter. Redmile Group LLC now owns 2,237,607 shares of the company’s stock valued at $89,728,000 after purchasing an additional 28,500 shares in the last quarter. DAFNA Capital Management LLC bought a new position in shares of WAVE Life Sciences during the 1st quarter valued at $1,780,000. Barclays PLC raised its holdings in shares of WAVE Life Sciences by 11.2% during the 1st quarter. Barclays PLC now owns 16,201 shares of the company’s stock valued at $650,000 after purchasing an additional 1,627 shares in the last quarter. Finally, UBS Group AG raised its holdings in shares of WAVE Life Sciences by 26.0% during the 1st quarter. UBS Group AG now owns 8,356 shares of the company’s stock valued at $335,000 after purchasing an additional 1,723 shares in the last quarter. Institutional investors own 81.41% of the company’s stock.

About WAVE Life Sciences

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Insider Buying and Selling by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Leave a Reply

Your email address will not be published. Required fields are marked *